Kymera Therapeutics Inc logo

Kymera Therapeutics Inc

$ 23.20 +1.13 (+5.12%) 10:58 AM EST
P/E:
At Loss
P/B:
2.88
Market Cap:
$ 1.26B
Enterprise V:
$ 832.34M
Volume:
67.82K
Avg Vol (2M):
696.18K
Volume:
67.82K
Market Cap $:
1.26B
PE Ratio:
At Loss
Avg Vol (2-Month):
696.18K
Enterprise Value $:
832.34M
PB Ratio:
2.88
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
Name Current Vs Industry Vs History
Cash-To-Debt 22.69
Equity-to-Asset 0.76
Debt-to-Equity 0.04
Debt-to-EBITDA -0.13
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.91
Distress
Grey
Safe
Beneish M-Score -0.42
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 35.69
9-Day RSI 34.03
14-Day RSI 37.2
6-1 Month Momentum % -34.77
12-1 Month Momentum % -51.67

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.6
Quick Ratio 4.6
Cash Ratio 4.48
Days Sales Outstanding 5.51

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -36.8

Financials (Next Earnings Date:2022-11-10 Est.)

KYMR's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:KYMR

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 56.747
EPS (TTM) ($) -2.71
Beta 0
Volatility % 90.02
14-Day RSI 37.2
14-Day ATR ($) 1.996499
20-Day SMA ($) 25.619
12-1 Month Momentum % -51.67
52-Week Range ($) 13.15 - 69.12
Shares Outstanding (Mil) 54.71

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Kymera Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Kymera Therapeutics Inc Analysis

Share your research

Headlines

See More
No news.